Newswise Researchers at Case Western Reserve University School of Medicine have identified a genetic factor that prevents blockages from forming in blood vessels, a discovery that could lead to new therapies for cardiovascular diseases. The findings are described in the Nov. 19 issue of the Journal of Clinical Investigation. Researchers led by Mukesh K. Jain, MD, FAHA, professor of medicine, Ellery Sedgwick Jr. Chair and director of Case Cardiovascular Research Institute at Case Western Reserve School of Medicine, found that a shortage of the genetic factor KLF4, which regulates endothelial cells lining the interior of blood vessels, makes the lining more prone to the buildup of harmful plaque and fat deposits. In addition they showed that the deficiency of KLF4 also made the blood vessel more susceptible to clot formation. The plaque buildup (called atherosclerosis) narrows vessels and provides the foundation for clot formation (called thrombosis) that leads to heart attack and stroke. Conversely, sufficient levels of KLF4, protect the inner lining of blood vessels, from toxins and other harmful agents that trigger the buildup of plaque and clot formation. This research answers a fundamental question in blood vessel health, identifying KLF4 as a master regulator of the most cardinal … Continue reading →

A startup called GenePeeks will identify recessive diseases that could show up in children of sperm-bank clients and donors. Within the next year, women choosing a sperm donor may be able to use a genetic-analysis service that identifies those with DNA that could cause disease if combined with their own. Sperm donors are already screened for a handful of genetic conditions, and recipients can choose between donors based on qualities such as height, athleticism, and education. A more detailed analysis of how donor DNA would combine with the recipients DNA would be the next step. A company called GenePeeks will use DNA-scanning microarrays, which are cheaper to use than whole-genome sequencing, to examine the roughly 250,000 DNA bases in the genomes of sperm-bank clients and donors. The company will then use what's known about how DNA is mixed and divided during egg and sperm formation to compute thousands of virtual child genomes. Each of these virtual genomes will then be analyzed for disease risks. Donors that produced virtual babies that inherited a genetic disease can then be excluded. GenePeeks is about six months away from launching its service and will soon announce its initial partner sperm bank, says CEO Anne … Continue reading →

Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v http://www.newininstitute.com.au PRP Therapy was chosen instead of a Hair Transplant to treat an area of hair loss in a female. 2 month comparison Before and After photos show a highly successful outcome. Note that continued hair growth will occur over the coming months. Another procedure will need to be performed at around the peak period: 12-18 months when growth begins to slow. Newin Institute has uniquely developed processes and protocols for PRP and Adipose Stem Cell Therapy.From:Rhett BosnichViews:1 0ratingsTime:00:55More inScience Technology Follow this link: Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v - Video … Continue reading →

ScienceDaily (Nov. 19, 2012) A research team at Georgetown Lombardi Comprehensive Cancer Center say the new and powerful cells they first created in the laboratory a year ago constitute a new stem-like state of adult epithelial cells. They say these cells have attributes that may make regenerative medicine truly possible. In the November 19 online early edition of the Proceedings of the National Academy of Sciences (PNAS), they report that these new stem-like cells do not express the same genes as embryonic stem cells and induced pluripotent stem cells (iPSCs) do. That explains why they don't produce tumors when they grow in the laboratory, as the other stem cells do, and why they are stable, producing the kind of cells researchers want them to. "These seem to be exactly the kind of cells that we need to make regenerative medicine a reality," says the study's senior investigator, chairman of the department of pathology at Georgetown Lombardi, a part of Georgetown University Medical Center. This study is a continuation of work that led to a breakthrough in December 2011 when Schlegel and his colleagues demonstrated that he and his team had designed a laboratory technique that keep both normal as well … Continue reading →

SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate product usingmice models for testing.Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study. The results of Regen's study will provide the safety profile data required for filing of anInvestigational New Drug (IND) application for the product with the US Food and Drug Administration .Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014. HemaXellerate offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions."Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone … Continue reading →

The Irish Times - Monday, November 19, 2012 CLAIRE O'CONNELL Could a particular type of adult stem cell offer a useful therapy for diabetes? An EU-funded project being led by NUI Galway hopes to find out. The 6 million Reddstar project will assess whether the stem cells can tackle glucose levels and various complications of diabetes, including diabetic ulcers and eye, nerve, heart and kidney and bone damage. The approach centres on a specific adult stem-cell population owned by Orbsen Therapeutics, a spin-out from the Science Foundation Ireland-funded Regenerative Medicine Institute (Remedi) at NUI Galway. Initially, the project will develop ways to grow the bone-marrow-derived stem cells in a way that is useful for trials, according to company co-founder and Remedi director Prof Tim OBrien. The cells will then be tested in several preclinical models of diabetic complications at centres in Galway, Belfast, Munich, Berlin and Porto. Then the plan is to select one complication for which the adult stem cells will be assessed in human trials in Denmark. The three-year EU funding will support nine jobs in Ireland, five of which will be in Orbsen Therapeutics, according to CEO Brian Molloy, who says the project should help to build … Continue reading →

Liposomes are used in contemporary medicine to carry and apply drugs and genes into different tissue areas of the body. They are small bubble-shaped lipid molecules, and an attractive candidate for delivery because they are composed of the same material as cell membranes. Several types of cancer, for instance, are treated with liposome therapy. Nano-sized liposomes would remarkably improve the precision and effectiveness of drug and gene delivery. A few such technologies already exist in the market and in clinical use, but cell-specific delivery is still a property to be explored in nanomedicine. Sanjeev Ranjan has studied the use of liposome nanoparticles in the treatment of inner ear disorders. His doctoral dissertation for the Aalto University Department of Biomedical Engineering and Computational Science looks into the manufacturing of nanoliposomes, their use in drug and gene delivery, and also into imaging techniques. With further research Ranjan expects all these properties to be combined into a single multifunctional nanoparticle. "Liposomes are currently the most advanced nanoparticles for delivering drugs and genes in vivo. Their main problem is that they cannot be exactly targeted to desired cells with high efficiency," Ranjan points out. Ranjan's research has been a part of the EU-funded project … Continue reading →

Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v http://www.newininstitute.com.au PRP Therapy was chosen instead of a Hair Transplant to treat an area of hair loss in a female. 2 month comparison Before and After photos show a highly successful outcome. Note that continued hair growth will occur over the coming months. Another procedure will need to be performed at around the peak period: 12-18 months when growth begins to slow. Newin Institute has uniquely developed processes and protocols for PRP and Adipose Stem Cell Therapy.From:Rhett BosnichViews:1 0ratingsTime:00:55More inScience Technology See more here: Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v - Video … Continue reading →

What Are Stem Cells and Stem Cell Therapy Stemenhance http://www.stemcellproduct.net This video gives you the definition, facts, and understanding on what are stem cells, that there are two of them embryonic and adult stem cells, how they work and the uses of stem cell when the tissue is affected in your body and how messengers signal the bone marrow to release adult stem cells to help in the repair of the injured tissue. Why this information is exciting for me to do a video is because I see stemcells as the best way of how to produce optimal health in your body. The way I look at it is that optimal health equals the number of healthy cells in your body and the only way the body repairs a damaged area is by creating and sending adult stem cells to that area. That's why I'm introducing a stem cell product from a nutrition company who patented a stem cell enhancer which supports the release of adult stem cells. What will also excite you too is that Stemtech (the stemcell company) has also come out with two other products that will also optimize the circulation of these stem cells … Continue reading →

SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate product usingmice models for testing.Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study. The results of Regen's study will provide the safety profile data required for filing of anInvestigational New Drug (IND) application for the product with the US Food and Drug Administration .Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014. HemaXellerate offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions."Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone … Continue reading →